Eckert & Ziegler  has signed an agreement with the U.S. pharmaceutical company Ratio Therapeutics Inc. for the joint development and manufacture of innovative radiopharmaceutical products based on Lu-177 and Ac-225. The agreement covers the development of a validated manufacturing process as well as the GMP-compliant production of clinical investigational products. Ratio Therapeutics will use the newly built GMP suites at the Eckert & Ziegler production site near Boston, MA, USA, from July 2022 for this purpose.

To read more please visit:

Eckert & Ziegler Becomes Contract Manufacturer for Clinical Development Candidates Based on Lutetium-177 and Actinium-225

Source: Eckert&Ziegler